# A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

> **NCT03158025** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 39 (actual)

## Conditions studied

- Insomnia Disorders

## Interventions

- **DRUG:** Zolpidem tablets
- **DRUG:** Suvorexant tablets, over-encapsulated
- **DRUG:** Lemborexant tablets
- **DRUG:** Placebo lemborexant
- **DRUG:** Placebo zolpidem
- **DRUG:** Placebo suvorexant

## Key facts

- **NCT ID:** NCT03158025
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-19
- **Primary completion:** 2018-07-04
- **Final completion:** 2018-07-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158025, "A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03158025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*